We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Oncology

Journal Scan / Research · September 04, 2014

Addition of Bevacizumab to Erlotinib as First-Line Treatment in EGFR-Mutated NSCLC

The Lancet Oncology

 

Additional Info

The Lancet Oncology
Erlotinib Alone or With Bevacizumab as First-Line Therapy in Patients With Advanced Non-Squamous Non-Small-Cell Lung Cancer Harbouring EGFR Mutations (JO25567): An Open-Label, Randomised, Multicentre, Phase 2 Study
Lancet Oncol 2014 Oct 01;15(11)1236-44, T Seto, T Kato, M Nishio, K Goto, S Atagi, Y Hosomi, N Yamamoto, T Hida, M Maemondo, K Nakagawa, S Nagase, I Okamoto, T Yamanaka, K Tajima, R Harada, M Fukuoka, N Yamamoto

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading